Primary Immunodeficiency
Full review of systems/assessment is done by Kaba RNs when?
At every visit
Common clinical tool used to assess MG patients
MG-ADL
This clinical tool is used to assess Autoimmune Neuropathy
Modified RANKIN or INCAT
Initial assessments are completed _______ and reassessments are completed ________
Prior to start of care (SOC); prior to each subsequent dispense
Pharmacy assessment occurs....?
Monthly, and the frequency of therapy
This MG drug on our formulary also requires drug-specific clinical assessment at initial, at 3 months and every 6 months.
Vyvgart
Three examples of diseases associated with autoimmune neuropathy
CIDP, SFN, MMN, GBS, Stiff person syndrome
Should be client individualized and developed within 72 hours of start of care
Nursing plan of care/treatment
Three examples of diseases associated with Primary Immunodeficiency
CVID, SAD, Hypogam, IgG subclass deficiency
The urgency for this disease-state specific initial assessment?
Identifying signs of exacerbation
This device is used to measure grip strength for clients with neuro or musculoskeletal diagnosis
Dynamometer
Medication reconciliation is done at this interval by nursing
During admission and all subsequent visits
Three hallmark criteria you look for during the initial assessment
History of recurrent infection
Use of antibiotics
Laboratory data: IgG levels and titers
Frequency of MG-ADL score for IVIG
Initial, at 3 months and every 6 months
This autoimmune neuropathy disease requires urgent specific assessment
GBS and Stiff Person's
Patients require a ______assessment (chronic or acute) after completion of first cycle of therapy.
24-48h
Immunodeficiency clinical assessment for IVIG occurs...?
Initial, at 3 months and then at 6 months
This MG medication requires both intake/pharmacy initial assessment and drug-specific reassessment with every fill
Rystiggo
Autoimmune neuropathy clinical assessment for IVIG occurs......?
Initial, 3 months and every 6 months.
Kaba fusion policy and ACHS standards governing patient assessment and plan of care
Policy 8.3 and DRX 5-2B/2C